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ABSTRACT
Introduction This study reports the 30- day mortality, 
SARS- CoV-2 complication rate and SARS- CoV-2- related 
hospital processes at the peak of the first wave of the 
pandemic in the UK.
Methods This national, multicentre, cohort study at 74 
centres in the UK included all patients undergoing any 
surgery below the elbow at the peak of the UK pandemic. 
The primary outcome measure was 30- day postoperative 
mortality and was assessed in all enrolled patients. The 
secondary outcomes were SARS- CoV-2 complication 
rates and overall complication rates. A clinician survey 
relating to SARS- CoV-2 safety processes was carried out 
for each participating centre.
Results This analysis includes 1093 patients who 
underwent upper limb surgery from the 1 to 14 April 
2020 inclusively. The overall 30- day mortality was 
0.09% (1 pre- existing SARS- CoV-2 pneumonia) and 
the mortality of day case surgery was zero. Most 
centres (96%) screened patients for symptoms prior to 
admission, only 22% routinely tested for SARS- CoV-2 
prior to admission. The SARS- CoV-2 complication rate 
was 0.18% (2 pneumonias) and the overall complication 
rate was 6.6% (72 patients). Both SARS- CoV-2- related 
complications occurred in patients who had been 
hospitalised for a prolonged period before their surgery 
and a total of 19 patients (1.7%) were SARS- CoV-2 
positive.
Conclusions The SARS- CoV-2- related complication 
rate for upper limb surgery even at the peak of the UK 
pandemic was low at 0.18% and the mortality was 
zero for patients admitted on the day of surgery. Urgent 
surgery should not be delayed pending the results 
of SARS- CoV-2 testing. Routine SARS- CoV-2 testing 
for day case upper limb surgery not requiring general 
anaesthesia may be excessive and have unintended 
negative impacts.
INTRODUCTION
The SARS- CoV-2 pandemic has had 
significant implications for the delivery 
of both urgent and planned surgical 
services around the world. In April in the 
UK, the daily number of lab- confirmed 
cases peaked, and daily number of deaths 
reached a plateaued peak.1 At this time 
point planned and elective surgery was 
largely stopped, while urgent and emer-
gency surgery continued, in the context 
of more limited access to theatres and 
with modified perioperative practices.
A recent global cohort study demon-
strated that postoperative pulmonary 
complications occurred in half of patients 
with perioperative SARS- CoV-2 infection 
and were associated with high mortality.2 
However, there are significant potential 
issues regarding the meaning and gener-
alisability of this study; there are meth-
odological concerns as regard the way in 
which patients were selected for inclu-
sion, and it is arguable that they cannot 
be generalised to surgery of the upper 
extremity and more minor surgery under 
local anaesthetic, given the case mix.
Recently, planned care has started to 
resume in the UK, with guidance from 
NHS England and the British Orthopaedic 
Association both emphasising the need to 
separate the elective pathways from the 
emergency pathways.3 4 This guidance has 
advised SARS- CoV-2 testing for all emer-
gency and elective admissions (including 
day surgery), and 14 days of self- isolation 
for the family units of any patient under-
going elective surgery. This guidance is 
proposed despite a substantial drop in 
both the daily number of lab- confirmed 
cases and daily deaths. More recently, the 
National Institute for Health and Care 
Excellence has published recent guid-
ance relating to planned care which has 
advised comprehensive social distancing 
and hand hygiene measures for 14 days 
before any admission, a SARS- CoV-2 test 
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3 days before admission and self- isolation from the 
day of the test until admission.5 Questions remain 
regarding the ongoing delivery of both urgent and 
planned surgery in the context of the current global 
SARS- CoV-2 surges.
Aims and objectives
Given that a significant volume of surgery continued 
during the pandemic peak in the UK, our aim was to 
assess the safety of upper extremity surgery below the 
elbow that was carried out at this time when it was 
not feasible or advisable to isolate family units for 14 
days before surgery or routinely test for SARS- CoV-2 
before surgery. Specifically, our primary objective was 
to assess the 30- day mortality of patients undergoing 
upper extremity surgery below the elbow at the peak 
of the pandemic. Our secondary objectives were to 
assess the SARS- CoV-2- related complication rate, the 
non- SARS- CoV-2 complication rates, the re- opera-
tion rate and the nature of local SARS- CoV-2 hospital 
safety processes.
METHODS
We carried out a national multicentre observational 
cohort study in patients undergoing any form of upper 
extremity surgery below the elbow with or without 
SARS- CoV-2 infection at 74 institutions in the UK. 
We collected only routine, anonymised data with no 
change to clinical care pathways. The study was regis-
tered at each site as a service evaluation project; and at 
the lead centre (Nuffield Orthopaedic Centre), it was 
approved by the clinical audit team, with registration 
number 6091.
Participants
Each participating institution included all patients 
undergoing any form of upper extremity surgery 
below the elbow from 1 April to 14 April inclusive, this 
included the Easter bank holiday weekend. Surgery 
was defined as any procedure done in any form of 
operating theatre or procedure room under general, 
regional or local anaesthesia. Patients undergoing 
surgery for any indication were eligible, including 
benign disease, cancer, trauma, infection and nerve 
compression. The study included children and adults. 
Patients having surgery on other body parts in addition 
to the hand/wrist procedure, whether this was at the 
same sitting or another sitting during the same hospital 
episode, were excluded.
Participating hospitals used both electronic and 
paper records in order to identify all patients fulfilling 
the eligibility criteria. Several units had gathered a 
patient list prospectively, while others gathered data 
retrospectively. Site investigators were provided with a 
range of written materials including a protocol which 
detailed the specifics of eligibility and data input. Due 
to the lack of widespread SARS- CoV-2 testing at this 
time point, there was a concern that including only 
those who tested positive would introduce a signifi-
cant degree of bias into the study, and it was acknowl-
edged that it would be likely that a number of patients 
included within the study would be asymptomatic 
positives, but there would be no way of defining the 
exact size of this subgroup.
The clinician survey was completed remotely in elec-
tronic format by the lead consultant surgeon for each 
institution. This survey was piloted locally and if any 
questions were unclear then these were addressed by 
email or telephone communication. Level 2 personal 
protective equipment (PPE) was defined as at least 
an FFP3 respirator mask, eye protection and surgical 
gown. Level 1 was a surgical gown with a fluid- resistant 
surgical mask.
Patient data
Data were collected from the patient record using a 
standardised Excel spreadsheet and securely returned 
by the lead author via institutional email or secure file 
transfer. Demographic variables recorded included 
age, sex, specific comorbidities, smoking status. The 
SARS- CoV-2 status was recorded as positive (positive 
swab PCR presurgery, positive swab PCR postsur-
gery, CT chest positive presurgery, CT chest positive 
postsurgery, chest X- ray (CXR) or clinical suspicion 
presurgery, CXR or clinical suspicion postsurgery) or 
negative (no suspicion, no suspicion and swab PCR 
negative presurgery). Clinical diagnosis consistent with 
SARS- CoV-2 infection was made by a senior physician 
and based on clinical presentation of symptoms highly 
indicative of SARS- CoV-2 infection, including cough, 
fever and myalgia.
Operative variables included indication for surgery 
(trauma, infection, cancer, nerve compression, other), 
procedure completed and anaesthesia used (local 
with epinephrine, local without epinephrine, local 
with sedation, regional, regional and local, regional 
with sedation±local, general only, general and local, 
general and regional and other). Emergency surgery 
was defined as procedures classified by the National 
Confidential Enquiry into Patient Outcome and Death 
as immediate, urgent or expedited. The senior local 
principal investigator for each hospital was asked to 
confirm data completeness and that all eligible patients 
had been entered into the database. The length of stay, 
and nature of surgical follow- up were also recorded.
Outcomes
The primary outcome was 30- day mortality, with the 
day of surgery defined as day 0. The other secondary 
outcome measures were the rate of SARS- CoV-2 
complications, the rate of non- SARS- CoV-2 compli-
cations and re- operation rate. The specific compli-
cations recorded were COVID-19 pneumonia, acute 
respiratory distress syndrome (ARDS), intensive care 
unit (ICU) admission, sepsis, renal failure, superficial 
infection, deep infection, tendon rupture, nerve injury, 
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fracture displacement, chronic regional pain syndrome 
and other. A SARS- CoV-2 complication was defined 
as any patient with any form of positive COVID-19 
status and any form of COVID-19- related complica-
tion (COVID-19 pneumonia, ARDS, ICU admission, 
renal failure, sepsis).
Statistical analysis
The study was done according to STROBE guidelines 
for observational studies.6 Summary statistics (mean, 
SD, median and IQR) were calculated for continuous 
variables and number of observation and percentages 
used for categorical data. Patient data were summa-
rised by the occurrence of an outcome event, if suffi-
cient events were considered to have taken place.
Logistic regression was used to assess the associa-
tion of key variables of interest with occurrence of a 
complication with 30 days of surgery, and ORs and 
95% CIs calculated. Due to the relatively low event 
rates, modelling of any complication (not mortality 
or re- operation) were carried out. Additionally, 
the number of variables was limited with an overall 
comorbidity variable (any one or more of hyperten-
sion, ischaemic heart disease, diabetes, stroke/tran-
sient ischaemic attack, chronic obstructive pulmonary 
disease or chronic kidney disease) prior to any model-
ling. Factors included in the model were age, gender, 
comorbidity (one or more vs none), smoking, surgical 
indications (infection or non- infection), urgency of 
surgery (urgent/immediate or not), regional/general 
anaesthetic or not and tourniquet use. A sensitivity 
analysis adjusted for potential clustering by centre 
using generalised estimating equation (GEE) model 
with logit function and assuming exchangeable correla-
tion structure with Huber- White Sandwich variance 
estimator. Analyses were done using Stata V.15.1.
RESULTS
Centres
In total 74 UK centres participated (see table 1 for 
characteristics), of which 17 (23%) were designated 
major trauma centres and 28 (38%) had a dedicated 
hand on- call service. The vast majority (72 centres, 
97%) stopped all elective surgery, with most stopping 
elective surgery by 22 March. The median catchment 
population was 500k (IQR 350k–780k). At only 24 
surgical centres (32%) did surgeons assess patients 
clinically for the first time on the day of surgery.
Surgical capacity
Most centres had access to a dedicated daily theatre 
list with general anaesthesia availability (58 centres, 
78%), while around half had daily access to regional 
anaesthesia (36 centres, 49%). Details on the facilities 
used by centres are provided in table 2. Main thea-
tres were used by 70 centres (95%) during this time 
period, and in 6 centres (8%) this was new capacity 
in main theatres as a result of the pandemic. A minor 
ops theatre was used by 20 centres (26%) and in 7 
centres (9%) this was new capacity. A clinic procedure 
room was used by 31 centres (42%), and in 15 centres 
(20%) this was new capacity. An emergency depart-
ment procedure room was used by 23 centres (31%), 
and in 8 centres (11%) this was new capacity. Theatre 
in a private hospital was used by 19 centres (26%) and 
in 16 centres (22%) this was new capacity.
SARS-CoV-2 safety processes
Additional centre SARS- CoV-2- related precautions 
are summarised in table 3. Screening questions were 
used by 71 centres (96%) and questions about contacts 
by 37 centres (50%). SARS- CoV-2 swab PCR was not 
undertaken for any patients in 54 centres (73%). In 18 
centres (24%), SARS- CoV-2 swabbing was performed 
routinely, in two centres (3%) swabbing began during 
the study period, in one centre (1%) it was performed 
for inpatient cases and not day case surgery, and in one 
centre (1%) it was performed for general anaesthetic 
(GA) cases only. Chest imaging (X- ray or CT) was 
conducted in just three centres (4%). A dedicated day 
surgery unit was available for all day surgery patients 
in 35 centres (47%) and for some day surgery patients 
in 16 centres (22%). In centres in which patients were 
first assessed face to face by the surgeon on the day of 
surgery, the median proportion of patient cancelled on 
the day was 10% (IQR 5%–30%).
Patients were kept fully isolated from known SARS- 
CoV-2- positive patients in 72 centres (97%) and 
partially in 2 centres (3%). For soft tissue surgery, 
23 centres (31%) used level 1 PPE, 36 centres (49%) 
used level 2 and 15 centres used a mixture (20%). For 
Table 1 Centre characteristics
Variable n (%)*
Major trauma centre 17 (23)
Population size 709 (753); 500 (350, 780)
Dedicated 24- hour on- call specialist service 28 (38)
Were patients assessed for the first time in person on the day of surgery?
  No 45 (61)
  Yes 24 (32)
  Unsure 5 (7)
Date stopping of elective practice
Stopped 72 (97)
  8–14 March 7 (10)
  15–21 March 37 (51)
  22–28 March 22 (31)
  29 March–1 April 6 (8)
Daily general anaesthesia access 58 (78)
Daily regional anaesthesia access
  No 36 (49)
  Yes 36 (49)
  Unsure 2 (3)
Mean (SD); median (IQR) is given for continuous variables instead of n 
(%), n=74.
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surgery which involved drilling into bone 64 centres 
(86%) used level 2 PPE, 6 centres (8%) used a mixture 
and 4 centres (5%) used level 1. Hospital policy was 
for patients to wear a face mask at all times in 13 
centres (18%), just for the surgery in 19 centres (26%), 
no mask wear policy in 37 centres (50; respondents 
were unsure in 5 centres (7%)).
When asked regarding the surgical procedures 
concerning an urgent case of a patient with suspected 
or proven SARS- CoV-2 infection requiring urgent 
surgery, all centres (100%) stated that this involved 
the use of full level 2 PPE and patient isolation. In 41 
centres (55%), procedures did not involve a specific 
designated theatre or ward, in 14 centres (19%) proce-
dures involved a specific designated theatre without a 
specific designated ward, in 11 centres (15%) proce-
dures involved a specific designated theatre and ward, 
while in the remaining 8 centres (11%) procedures 
involved a specific designated ward without a specific 
designated theatre.
PATIENTS
The patient demographics are shown in table 4. A total 
of 1093 patients underwent upper limb surgery from 
1 to 14 April 2020 inclusively at the 74 centres. There 
were 698 males and 395 females, mean age 42 (SD 21) 
years. A total of 152 patients (13.9%) were under 18 
years of age.
SURGERY
The details relating to surgery are shown in table 5. 
The most common indications for surgery were 
trauma (88%) and infection (8%). Overall, 915 (84%) 
procedures were undertaken as a day case; 330 proce-
dures were done under GA (30%), of which 206 (62%) 
were as a day- case, 188 under regional block (17%), of 
which 157 (84%) were discharged on the same day 
and 575 under local anaesthetic only (53%), and of 
these 363 (70%) were a day- case.
Mortality and complications including SARS-CoV-2 
status
The complications and factors associated with compli-
cations are shown in tables 6 and 7. The overall 30- day 
mortality was 0.09% (one SARS- CoV-2 pneumonia) 
and the mortality of day- case surgery was zero. The 
only death reported was in a patient over 60 years of 
age who had been already hospitalised with a suspected 
SARS- CoV-2 pneumonia who later during this medical 
Table 2 Facilities used for surgery
(n (%))
Main theatre
  No 4 (5)
  Yes and not used pre- COVID 6 (8)
  Yes and used pre- COVID 64 (87)
Minor ops theatre
  No 54 (73)
  Yes and not used pre- COVID 7 (9)
  Yes and used pre- COVID 13 (18)
Clinic procedure room
  No 43 (58)
  Yes and not used pre- COVID 15 (20)
  Yes and used pre- COVID 16 (22)
Procedure room in Emergency Department
  No 51 (69)
  Yes and not used pre- COVID 8 (11)
  Yes and used pre- COVID 15 (20)
Theatre in private hospital
  No 55 (74)
  Yes and not used pre- COVID 16 (22)
  Yes and used pre- COVID 3 (4)
Table 3 Additional COVID- related precautions
Variable n (%)*
Pre- admission symptoms screening questions
  No 2 (3)
  Yes 71 (96)
  Unsure 1 (1)
Potential contacts questions
  No 18 (24)
  Yes 37 (50)
  Unsure 19 (26)
COVID-19 swab
  No 54 (73)
  Yes 18 (24)
  Yes—only certain patients 2 (3)
Pre- op chest X- ray or CT 3 (4)
Proportion of cancellation (n=39) 25 (29); 10 (5, 30)
Patients isolated from known COVID-19- positive patients
  Yes—all 72 (97)
Mask policy
  Yes—at all times 13 (18)
  Yes—surgery only 19 (26)
  No 37 (50)
  Unsure 5 (7)
PPE level bone
  1 4 (5)
  Mixture of 1 and 2 6 (8)
  2 or above 64 (86)
PPE level soft tissue
  1 23 (31)
  Mixture of 1 and 2 15 (20)
  2 or above 36 (49)
Procedure for urgent SARS- CoV-2- positive cases
  PPE/Isolation only 41 (55)
  PPE/Isolation+theatre+ward 11 (15)
  PPE/Isolation+ward only 8 (11)
  PPE/Isolation+theatre only 14 (19)
Mean (SD), median (IQR) is given for continuous variables instead of n 
(%), n=74.
PPE, personal protective equipment.
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admission developed a bacterial hand infection which 
required surgical treatment; this patient’s SARS- CoV-2 
treatment was subsequently not escalated beyond the 
ward level due to medical comorbidity.
The SARS- CoV-2 complication rate was 0.18% 
(2 pneumonias, including the mortality above, both 
confirmed by swab or CT) and the overall complica-
tion risk of 6.6% (72 patients). Both SARS- CoV-2- 
related complications occurred in patients who had 
been hospitalised for a prolonged period before their 
upper extremity surgery as part of this study. The 
non- fatal SARS- CoV-2 pneumonia was in a patient 
who had multiple debridements for a degloving injury 
of the upper limb as an inpatient and developed the 
SARS- CoV-2 pneumonia clinically after the third oper-
ation. A total of 19 patients (1.7%) were SARS- CoV-2 
positive of which 17 were confirmed before surgery 
(2 on swab, 15 on CXR/clinical suspicion) and 2 after 
surgery (1 on swab and 1 on CT).
The most common complications were bacterial 
surgical site infection in 33 cases (3%), tendon rupture 
in 9 cases (0.8%) and fracture displacement in 7 cases 
(0.6%). Most centres (71.96%) were only screening 
patients for symptoms prior to admission and only 
20 (24%) were carrying out SARS- CoV-2 swabbing. 
Findings from the logistic regression of factors with 
occurrence of any complications in table 7. There was 
an association of greater age, surgical indication (infec-
tion) and regional or GA use with increased likelihood 
of a complication when analysed concurrently (results 
Table 5 Surgery- related characteristics
Surgery- related characteristics n (%)5
Variable
Postsurgery complications
TotalNo (n=1021) Yes (n=72)
Urgency of surgery
  Urgent 345 (34) 31 (43) 376 (34)
  Expedited 645 (63) 39 (54) 684 (63)
  Immediate 15 (1) 2 (3) 17 (2)
  Elective 16 (2) 0 (0) 16 (2)
Surgery indications
  Trauma 910 (89) 52 (72) 962 (88)
  Infection 74 (7) 17 (24) 91 (8)
  Cancer 13 (1) 0 (0) 13 (1)
  Nerve compression 2 (0) 1 (1) 3 (<1)
  Other 22 (2) 2 (3) 24 (2)
Anaesthetic
  Local without epinephrine 363 (36) 13 (18) 376 (34)
  Local with epinephrine 188 (18) 11 (15) 199 (18)
  General only 144 (14) 17 (24) 161 (15)
  General and local 130 (13) 12 (17) 142 (13)
  General and regional 24 (2) 3 (4) 27 (2)
  Regional only 115 (11) 13 (18) 128 (12)
  Regional and local 15 (2) 1 (1) 16 (2)
  Regional and sedation +/− 42 (4) 2 (3) 44 (4)
Procedure type
  Nailbed repair 75 (7) 3 (4) 78 (7)
  Soft tissue debride/closure/
terminalisation
322 (32) 17 (24) 339 (31)
  Flexor repair 79 (8) 14 (19) 93 (8)
  Extensor repair 66 (6) 6 (8) 72 (6)
  MUA±Cast/POP 136 (13) 5 (7) 141 (13)
  MUA+wire 55 (5) 5 (7) 60 (5)
  ORIF/ex fix 165 (16) 11 (15) 176 (16)
  Local/regional flap 9 (1) 0 (0) 9 (<1)
  Free flap 0 (0) 1 (1) 1 (<1)
  Nerve decompression inc. 
CTD
3 (<1) 1 (1) 4 (<1)
  Multiple flexors 8 (1) 2 (3) 10 (1)
  Multiple extensors 6 (1) 1 (1) 7 (1)
  Removal metalwork 27 (3) 1 (1) 28 (3)
  Vascular repair/replant 6 (6) 3 (4) 9 (1)
  Nerve repair±graft 43 (4) 1 (1) 44 (4)
  Other soft tissue 8 (1) 1 (1) 9 (1)
  Other bony 2 (<1) 0 (0) 2 (<1)
  Excision tumour/cancer 11 (1) 0 (0) 11 (1)
Procedure site
  Forearm 93 (9) 10 (14) 103 (9)
  Radius/Ulnar distal 239 (23) 17 (24) 256 (23)
  Carpus 23 (2) 3 (4) 26 (2)
  MCs including CMCJs 145 (14) 8 (11) 153 (14)
  P1 and P2 (zone 2 flexor) 327 (32) 26 (36) 353 (32)
  P3 (zone 1 flexor) 194 (19) 8 (11) 202 (18)
Tourniquet
  Yes, arm 368 (36) 36 (50) 404 (37)
  Yes, finger 199 (19) 9 (13) 208 (19)
  No 427 (42) 23 (32) 450 (41)
Continued
Table 4 Patient demographics
Patient demographics n (%)*
Variable
Postsurgery complications
TotalNo (n=1021) Yes (n=72)
Sex
  Male 651 (64) 47 (65) 698 (64)
  Female 370 (36) 25 (35) 395 (36)
Age (years) 41 (21); 50 (20); 42 (21);
40 (26 to 57) 49 (38 to 64) 41 (27 to 58)
Comorbidities
  Asthma 61 (6) 5 (7) 66 (6)
  Hypertension 115 (11) 12 (17) 127 (12)
  Ischaemic heart disease 25 (2) 7 (10) 32 (3)
  Diabetes 42 (4) 7 (10) 49 (4)
  Smoking 137 (13) 14 (19) 151 (14)
  Stroke/TIA 16 (2) 2 (3) 18 (2)
  COPD 18 (2) 2 (3) 20 (2)
  Chronic kidney disease 13 (1) 1 (1) 14 (1)
COVID-19 status
  No suspicion 997 (98) 65 (90) 1062 (97)
  Swab negative 9 (1) 3 (4) 12 (1)
  CXR/Clinical presurgery 12 (1) 3 (4) 15 (1)
  Swab/CT positive 
(presurgery/postsurgery)
3 (0) 1 (<1) 4 (<1)
Mean (SD), median (IQR) is given for continuous variables instead of n (%), n=1093.
COPD, chronic obstructive pulmonary disease; CXR, chest X- ray; TIA, transient ischaemic 
attack.
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of the GEE model were very similar and therefore not 
shown).
DISCUSSION
The SARS- CoV-2 complication rate for upper limb 
surgery at the peak of the UK pandemic was low at 
0.18% (two pneumonias). The overall 30- day mortality 
was 0.09% (one SARS- CoV-2 pneumonia) and the 
30- day mortality of day- case surgery was zero. Both 
these SARS- CoV-2- related complications occurred in 
patients who had been hospitalised for a prolonged 
period before their surgery, with the patient who died 
having been originally admitted for treatment of their 
SARS- CoV-2 pneumonia. At the peak of the pandemic, 
most centres (96%) were screening patients for symp-
toms prior to admission but only 22% were carrying 
out SARS- CoV-2 swabbing, and within this context 
we found that upper limb surgery conferred a low 
risk to patients. These findings support not delaying 
any urgent surgery pending the results of SARS- CoV-2 
testing, and they also support the continued resump-
tion of elective upper limb practice, particularly when 
conducted without general anaesthesia.
The most common complications were bacterial 
surgical site infection in 33 cases (3%), tendon rupture 
in 9 cases (0.8%) and fracture displacement in 7 cases 
(0.6%). These complication rates are comparable to 
reported rates in the literature.7–9 There was an asso-
ciation of greater age, surgical indication (infection) 
and regional or GA use with increased likelihood of 
a complication when analysed concurrently. Given 
infection was the most common complication, it is 
unsurprising that surgery for infection has a higher 
rate of postoperative complications, while the associ-
ation with regional or GA is likely related to the more 
severe infections not being amenable to surgery under 
local anaesthetic only and the fact that more severe 
infections have a higher complication rate.
One of the limitations of this study is the relatively 
low proportion of patients within this cohort who 
were SARS- CoV-2 positive in the perioperative period. 
However, around 70% of community SARS- CoV-2 
infections were asymptomatic in the UK,6 meaning that 
it is likely that a reasonable number of patients who 
underwent surgery in our cohort were SARS- CoV-2 
positive but asymptomatic, given that SARS- CoV-2 
prevalence was at its highest in April 2020. It is impos-
sible to precisely estimate prevalence in the UK as 
random community testing was not carried out at this 
time point, and later seroprevalence studies are likely 
to significantly underestimate actual prevalence due to 
poor test sensitivity and the likelihood of other forms 
of non- antibody- related immunity.10 11 The most 
recent high- quality UK data from the REACT study 
demonstrates a prevalence of around 0.2% in mid- May 
Surgery- related characteristics n (%)5
Variable
Postsurgery complications
TotalNo (n=1021) Yes (n=72)
  Unclear 27 (3) 4 (5) 31 (3)
Length of stay (days)
  0 873 (86) 42 (58) 915 (84)
  1 88 (9) 7 (10) 95 (9)
  2–10 55 (5) 14 (19) 69 (6)
  >10 4 (<1) 9 (13) 14 (1)
Follow- up
  Face- to- face (surgical team) 474 (47) 53 (74) 527 (48)
  Face- to- face (community 
team)
45 (4) 0 (0) 45 (4)
  Face- to- face (therapy) 155 (15) 11 (15) 166 (15)
  Remote (surgical team) 80 (8) 5 (7) 85 (8)
  Remote (therapy) 43 (4) 0 (0) 43 (4)
  None 222 (22) 3 (4) 225 (21)
CTD, carpal tunnel decompression; ex fix, external fixation; MUA, manipulation 
under anaesthetic; ORIF, open reduction and internal fixation; P1, proximal 
phalanx; P2, middle phalanx; P3, distal phalanx; POP, plaster of Paris.
Table 5 Continued
Table 6 Surgery outcomes
Variable Total
Status at 30 days
  Alive and at home 1086 (99)
  Alive in hospital 3 (<1)
  Died (day 1–7) 1 (<1)
Reoperation (30 days) 45 (4)
Complications (30 days)* 72 (7)
  SARS- CoV-2- related pneumonia 2 (1)
  ICU admission 1 (<1)
  Sepsis 1 (<1)
  Superficial infection 21 (2)
  Deep infection 12 (1)
  Tendon rupture 11 (1)
  Nerve injury 2 (<1)
  Fracture displacement 7 (1)
  Chronic regional pain syndrome 1 (<1)
  Other 15 (1)
*One individual had two complications—tendon rupture and a deep 
infection.
ICU, intensive care unit.
Table 7 Logistic regression of factors associated with 
occurrence of 30- day complication
Variables OR (95% CI) P value
Age 1.02 (1.00 to 1.03) 0.007
Gender 0.86 (0.50 to 1.48) 0.595
Comorbidity 1.34 (0.73 to 2 .43) 0.343
Smoking 1.56 (0.80 to 3.04) 0.188
Urgency of surgery 1.24 (0.72 to 2.12) 0.433
Surgery indications 3.71 (1.91 to 7.22) <0.001
Tourniquet use 0.86 (0.48 to 1.52) 0.596
Regional/General anaesthetic usage 3.31 (1.85 to 5.93) <0.001
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in similar age groups to those in our cohort, with a 
halving time of 8.6 days6; assuming this halving time 
was fairly constant from late March to May then this 
would mean that prevalence in early April was around 
5%–10%. Therefore, it is reasonable to estimate that 
in the order of 3.5%–7% of the patients in our cohort 
were asymptomatic carriers of SARS- CoV-2. This is 
consistent with the recently published data relating to 
trauma patients from London, which demonstrated a 
rate of SARS- CoV-2 infection of 7% and a peak prev-
alence in early April 2020.12
The persistence of SARS- CoV-2 circulating in the 
population poses a challenge to patient safety, staff 
safety and efficient perioperative care. However, there 
is a strong rationale and evidence base to support not 
delaying urgent surgery for trauma and infection as this 
will increase the rate of surgical complications.7 13 14 
Many complex decisions involving trade- offs between 
the short- term risks from SARS- CoV-2 exposure, and 
long- term risks associated with delaying effective 
planned surgical interventions for other pathologies, 
with much difficulty arising from uncertainties relating 
to our knowledge of SARS- CoV-2. In addition, there is 
a need to prevent cross- infection between patients and 
staff when attending hospital. Given the high mortality 
that has been reported in patients undergoing major 
surgery in the presence of SARS- CoV-2 infection, 
pathways have been developed to minimise patients’ 
risk of perioperative SARS- CoV-2 exposure.2 There 
are significant problems with the generalisability of 
these results to upper extremity surgery. There were 
very few cases of upper extremity surgery in COVID-
Surg, and by only including SARS- CoV-2- positive 
patients (based on the same definition as used in our 
study), the study cannot provide an accurate estimate 
for absolute risk in all SARS- CoV-2- positive patients, 
as patients with asymptomatic infections would 
rarely have been included and emerging evidence 
demonstrates the asymptomatic group constitutes an 
overall majority of positive patients.15 We therefore 
argue that the findings of COVIDSurg should not 
be applied universally to patients undergoing upper 
extremity procedures due to the lesser physiological 
insult conferred by the procedure and, in the case of 
operations performed without GA, the absence of a 
simultaneous period of insult to the respiratory system 
conferred by anaesthesia.
The prevalence of SARS- CoV-2 in the UK in August 
2020 was several levels of magnitude lower than in 
early April 2020. We would therefore argue that a 
more pragmatic approach is needed when it comes 
to the delivery of emergency and elective surgical 
services, and that this study can be of great use in terms 
of describing the risks within a pragmatic context. The 
context of our study is that in early April 2020 care 
pathways were not separate, patients were not advised 
against outdoor exercise and essential shopping 
trips and SARS- CoV-2 swabbing was not routinely 
performed. Within this context, the 30- day mortality 
was 0.09%, and the incidence of SARS- CoV-2- related 
complications was low at 0.18%, even in a cohort 
which consisted of many inpatient stays and large 
numbers of GA cases. Most of the surgery within our 
study was urgent and performed for trauma or infec-
tion. There is a strong argument that at the current 
time this urgent surgery should not be delayed solely 
for SARS- CoV-2 testing. The potential harms are clear 
in terms of delaying urgent surgery, particularly when 
it relates to contaminated wounds, tendon repair, 
infection and open fractures.7 13 16
The separation of pathways has created many logis-
tical difficulties in delivering both urgent and elec-
tive care, particularly in smaller centres which do not 
have separate sites to enable the physical separation 
patients having urgent and planned procedures. There 
are also many added costs due to additional processes 
such as the cost of swabbing, the logistics of admin-
istering the pathways and the costs of inefficiencies 
such as surgery postponed at the last minute due to a 
false positive swab test result. There are the additional 
social and economic impacts on the patients’ families 
of requiring shielding of the whole household pending 
and following surgical treatments.3 Routine swab-
bing may have a false negative rate of around 30%, 
meaning that at times it may falsely reassure, while as 
prevalence falls the proportion of positive tests that 
are true positives becomes increasingly minuscule.17 
The data from this study support performing day 
case upper limb surgery not requiring GA without 
routine SARS- CoV-2 testing in healthcare settings in 
which patient groups can be kept physically separate. 
This would enable those patients being treated under 
local or regional anaesthetic to remain distant from 
other patients in whom the potential implications of 
contracting SARS- CoV-2 would be likely to be more 
serious, for example, this may be via the use of a dedi-
cated minor operations facility.
We would therefore argue that, provided patients 
are screened for symptoms, kept isolated from other 
patients before and after surgery, wear a face mask in 
theatre and a basic level of PPE is worn by staff for 
all clinical encounters, day case upper limb surgery is 
safe. The findings will help clinicians inform patients 
regarding the relatively low real- world risks of under-
going upper extremity surgery while the threat of 
SARS- CoV-2 persists. The findings will also inform 
practice during future new surges, given that this study 
was carried out at the peak of the first wave of the 
pandemic.
CONCLUSIONS
The SARS- CoV-2- related complication rate for 
upper limb surgery at the peak of the first wave of 
the UK pandemic was low and the mortality was zero 
for patients admitted on the day of surgery. Urgent 
surgery should not be delayed pending the results of 
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SARS- CoV-2 testing. Routine SARS- CoV-2 testing 
for day case upper limb surgery not requiring general 
anaesthesia may be excessive and have unintended 
negative impacts.
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